SINOPHARM (01099) announced that its subsidiary, China National Medical Device Co., Ltd., recorded annual revenue of RMB 74.89 billion for the year ended December 31, 2025, representing a decrease of 2.35% compared to the previous year. Operating profit reached RMB 1.25 billion, an increase of 2.38% year-on-year. Comprehensive income attributable to owners of the parent company amounted to RMB 507 million, marking a growth of 25.64% compared to the prior year.